BOC Sciences Launched Inhibitors for Alzheimer's Diseases Studies

LONG ISLAND CITY, N.Y. - Nov. 1, 2016 - PRLog -- BOC Sciences launched inhibitors in accordance with Research areas. At present, there are three domains covered-cancer Immunotherapy, hsp90, alzheimer's disease. Inhibitors under these categories are classified into different groups as their targets differentiate.

For Alzheimer's diseases studies, inhibitors with 20 types of targets are presented, in total, about 250 inhbitors are included for the treatment studies of this disease. And the target (checkpoint immune proteins) number for cancer immunotherapy is 23. Hsp90 is an individual parallel target with the above two as it's quite promising for immune treatment.

BOC Sciences is still working to add more such categories to facilitate research chemical searching. It's estimated that about 2000 chemicals will be contained in such classifications according to their pharmaceutical functions. Besides, the company is also endeavoring to add as much as possible description or application details to its chemical products, and the change has been applied on this batch of inhibitors.

Other inhibitors that are under construction to provide better searching and purchasing experience are Quizartinib (http://www.bocsci.com/quizartinib-cas-950769-58-1-item-84...), GW3965 and hundreds of others. BOC Sciences with aim to be a comprehensive international chemical supplier has setting off. A one-stop supplier for pharmaceutical needs will be presented.

About Author

BOC Sciences is a professional pharmaceutical chemical supplier. The products it provides include inhibitors, APIs, GMPs, natural compounds and so on. Besides, the company also offers related services like custom synthesis, isotope labeling, fluorescent labeling, drug design and so on. The recent featured inhibitor products of the company are Cyt387 (http://www.bocsci.com/cyt387-cas-1056634-68-4-item-84-307...), WAY-252623 and etc.